AIM ImmunoTech (NYSEAMERICAN:AIM) Releases Earnings Results

AIM ImmunoTech (NYSEAMERICAN:AIM) released its quarterly earnings results on Monday. The company reported ($1.57) EPS for the quarter, FiscalAI reports. AIM ImmunoTech had a negative net margin of 13,360.33% and a negative return on equity of 1,586.23%. The business had revenue of $0.03 million during the quarter.

AIM ImmunoTech Stock Performance

AIM stock opened at $1.33 on Wednesday. The company has a market capitalization of $3.60 million, a P/E ratio of -0.05 and a beta of 1.03. The company has a fifty day moving average price of $2.36 and a 200-day moving average price of $5.33. AIM ImmunoTech has a 52-week low of $1.31 and a 52-week high of $36.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in AIM ImmunoTech stock. Corient Private Wealth LLC purchased a new stake in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned about 0.37% of AIM ImmunoTech at the end of the most recent quarter. Hedge funds and other institutional investors own 12.02% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on AIM. Zacks Research raised AIM ImmunoTech from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. Maxim Group upgraded shares of AIM ImmunoTech to a “strong-buy” rating in a research report on Friday, September 5th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Strong Buy” and an average target price of $450.00.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).